Nicking your finger with a knife while chopping some tomatoes for a salad is just a nuisance for most of us—we utter a choice word or two, rinse the cut, apply a disinfectant and maybe a band-aid, and then proceed to go on with our lives.
The same goes for, say, tripping and falling—most of us will just get up and keep on going, not giving the situation any more thought and barely noticing the bruise that may appear afterward.
Unfortunately, there are people whose very lives may be put in danger because of such seemingly minor accidents: hemophiliacs.
Hemophilia affects approximately 400,000 people worldwide, many of whom are not fully aware of their condition or are not getting the treatment they need.
Because a relatively small percentage of the world’s population suffers from hemophilia, many people are not aware just how serious this condition is and how much more difficult and dangerous it makes the lives of those who have it.
And this is where World Hemophilia Day comes in.
World Hemophilia Day Timeline
Early description by Abulcasis
The Andalusian surgeon Abu al-Qasim al-Zahrawi (Abulcasis) records families in which boys die from uncontrollable bleeding after minor injuries or circumcision, one of the earliest clinical descriptions of what is now recognized as hemophilia.
Otto identifies hereditary “bleeders”
Philadelphia physician John Conrad Otto publishes a paper describing a hereditary bleeding tendency in males within certain families and notes that healthy mothers can transmit the disorder, helping establish hemophilia as an inherited disease.
Hemophilia A and B distinguished
Researchers Alfredo Pavlovsky and Robert Gwyn Macfarlane independently show that not all hemophilia cases are the same, leading to the distinction between classic hemophilia (factor VIII deficiency, type A) and Christmas disease (factor IX deficiency, type B).
“Christmas disease” described
A British team led by Rosemary Biggs and R. G. Macfarlane publishes the case of Stephen Christmas, demonstrating a form of hemophilia caused by deficiency of a different clotting factor, now known as factor IX, and giving hemophilia B its original name, Christmas disease.
Clotting cascade and factor VIII role clarified
Macfarlane and other scientists outline the coagulation cascade and clarify the central role of factor VIII and factor IX in intrinsic coagulation, providing the biochemical framework that underpins modern diagnosis and replacement therapy for hemophilia.
Factor concentrates transform treatment
The development and widespread use of freeze‑dried factor VIII and IX concentrates allow people with hemophilia to treat bleeds at home, shifting care from hospital-based transfusions to on-demand and later prophylactic replacement therapy.
HIV crisis in hemophilia community
Before effective screening, many plasma-derived clotting factor products are contaminated with HIV and hepatitis C, leading to thousands of infections among people with hemophilia and prompting major reforms in blood safety and accelerated development of recombinant factors.
How to Celebrate World Hemophilia Day
Numerous events are organized every year on World Hemophilia day, filled with educational presentations and other events that promote an awareness of the disease and those who suffer from it.
If you are unable to attend, you could consider making a donation to the World Federation of Hemophilia to help support their fight against this debilitating condition, especially in the poorest parts of the world.
Another thing you could do is find the World Federation of Hemophilia’s Facebook page and proceed to share some of the many infographics they post in order to help your Facebook friends become more informed as well.
The same goes for Twitter—follow the World Federation of Hemophilia, and retweet their tweets about this day.
It may not seem like much at first glance, but social media has proven itself to be incredibly powerful on many occasions, especially when it comes to getting the word out about an important cause. Even the smallest of gestures can make a world of difference!
History of World Hemophilia Day
Hemophilia was first discovered in the 10th century, when physicians started to take a serious interest in people, especially males, who were bleeding to death after sustaining only minor injuries. At that time, it was called Abulcasis.
Unfortunately, due to the limited technology of the day, it was impossible to research the condition properly.
Numerous famous historical figures are thought to have had hemophilia, especially members of the European royal families, and it was often treated with aspirin which thinned the blood of the hemophiliac further, causing the symptoms to worsen.
Then, in 1803, Dr. John Conrad Otto of Philadelphia began to study people he called, “bleeders” more extensively, recognizing it to be a hereditary illness that was most often passed onto males from by their healthy mothers. In 1937, hemophilia was officially divided into two types: A and B.
Though no cure for hemophilia has been invented till this day, the sickness can be controlled by administering clotting factors on a regular basis in order to avoid spontaneous bleeding episodes.
World Hemophilia Day was created by the World Federation of Hemophilia in 1989, and the date it’s celebrated on, April 17th, was chosen in honor of the founder of the organization’s birthday, Frank Schnabel.
The day’s purpose is to raise awareness about the disease as well as other bleeding disorders and also to raise money for the treatment of those who cannot afford it.
Facts About World Hemophilia Day
Hemophilia Is Caused by Missing or Faulty Clotting Factors
Hemophilia results from a deficiency or dysfunction of specific proteins in the blood that are essential for forming stable clots.
In hemophilia A, the problem is with clotting factor VIII, while hemophilia B involves factor IX; both are coded by genes on the X chromosome.
When these factors are missing or do not work properly, the body can form only fragile clots, which break down prematurely and lead to prolonged bleeding, especially into joints and muscles.
A Genetic Condition That Mostly Affects Males but Can Also Occur in Females
Hemophilia is classically inherited in an X-linked recessive pattern, which means it primarily affects males who have only one X chromosome.
Females usually carry one altered copy of the gene and one healthy copy, but some women can develop hemophilia themselves if both X chromosomes carry the mutation or if the normal X is inactivated in many of their cells.
Female carriers may also experience significant bleeding symptoms, including heavy menstrual bleeding and postpartum hemorrhage.
Queen Victoria’s Family Helped Reveal the Hereditary Nature of Hemophilia
Hemophilia became widely known as “the royal disease” after it appeared in several descendants of Britain’s Queen Victoria in the 19th and early 20th centuries.
Genetic analysis of preserved remains from Victoria’s family has shown that they carried a mutation in the gene for factor IX, consistent with hemophilia B.
The spread of the condition through the royal families of Spain, Germany, and Russia provided some of the earliest high-profile evidence that hemophilia was inherited through maternal lines.
Blood Products for Hemophilia Once Transmitted HIV and Hepatitis
Before viral inactivation and screening methods were introduced in the mid-1980s, many people with hemophilia were treated with pooled plasma-derived factor concentrates that were not tested for blood-borne viruses.
Because these products were made from donations from thousands of people, a single infected donor could contaminate an entire batch.
In the United States and other countries, large proportions of patients with severe hemophilia became infected with HIV and hepatitis C, a tragedy that reshaped blood safety regulations worldwide.
Modern Prophylaxis Has Transformed Joint Health and Life Expectancy
Repeated bleeding into joints was once so common in severe hemophilia that many patients developed chronic pain, deformities, and disability at a young age.
With the introduction of prophylactic treatment, where clotting factor or newer non-factor therapies are given regularly to prevent bleeding episodes rather than just treat them, children with hemophilia in high-resource settings can now have near-normal joint function and life expectancy approaching that of the general population.
Hemophilia Is Rare but Appears in All Ethnic and Racial Groups
Hemophilia occurs in about 1 in 5,000 live male births for hemophilia A and about 1 in 25,000 to 30,000 live male births for hemophilia B.
Although historically associated with European royal families, the condition is found in every region of the world and affects people of all racial and ethnic backgrounds. A significant fraction of cases arise from new, spontaneous mutations in the hemophilia gene, with no prior family history.
Emerging Gene Therapy Targets the Root Cause of Hemophilia
New gene therapy approaches seek to correct hemophilia by delivering functional copies of the factor VIII or factor IX gene directly to a patient’s liver cells using modified viral vectors.
Early clinical trials have shown that some people with severe hemophilia can achieve near-normal clotting factor levels after a single infusion, dramatically reducing or eliminating spontaneous bleeding.
While questions remain about durability, safety, and access, gene therapy represents the first treatment designed to address the underlying genetic defect rather than simply replacing missing clotting factor.
